The US Food and Drug Administration’s Center for Drug Evaluation and Research in the past week issued its 12th novel approval of 2019 and the 20th biosimilar approval ever. Here are the recent developments in brief:
FDA gave accelerated approval to Genentech Inc.’s Polivy for use in a combination regimen for adults with diffuse large B-cell lymphoma that has progressed or returned after prior therapy